Join us for a Webinar on December 7
Please join us for a free webinar on cystic fibrosis to be held on Saturday, December 7, 2013 from 9:00 am to 1:00 pm MT (8:00 am PT/10:00 am CT/11:00 am ET). This event is being co-sponsored by the American Thoracic Society (ATS), the Cystic Fibrosis Foundation, Children’s Hospital Continue reading National Cystic Fibrosis Education Day Webinar December 7th, 2013
Large-scale screen also identified genes not previously linked to the disease
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Regensburg University, both in Germany, and the University of Lisboa, in Portugal, have discovered a Continue reading Potential new drug target for cystic fibrosis
Clinical trials are vital part of advancing treatments for CF patients. Fundraising is the genesis for new treatments because it allows researchers to create new treatments, but clinical trials are the bridge from a breakthrough in the lab to a new medicine actually being available on the open Continue reading Clinical Trials: A Vital Part of Cystic Fibrosis Treatment Advancements
At a cost of more than $300,000 a year, the new cystic fibrosis drug, Kalydeco, is one of the most expensive pills in American medicine. In early October, three doctors who treat cystic fibrosis patients said that kind of extremely high pricing for new drugs that treat rare conditions threatens the U.S. health care system and can’t be sustained.
Continue reading Cost of cystic fibrosis drug, others threatens system, doctors say
KaloBios Pharmaceuticals Inc. (KBIO) said the U.S. Food and Drug Administration granted orphan-drug designation for its treatment for cystic fibrosis patients with Pseudomonas aeruginosa. Continue reading KaloBios Says Cystic Fibrosis-Related Treatment Gains Orphan-Drug Status
JERUSALEM–(BUSINESS WIRE)–Oct. 14, 2013– Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI® (Tobramycin Inhalation Solution Continue reading Teva announces FDA approval of generic TOBI in the United States
Pharmaceutical discovery and development company Celtaxsys, Inc. today announced it is now enrolling patients for its first trial of CTX-4430 oral treatment for lung disease in Cystic Fibrosis (CF) patients. In this study, the safety and Continue reading Celtaxsys Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients
Since becoming an independent company late last year, AbbVie has been making significant progress. AbbVie shares have been among the best performers in the health care sector this year, gaining nearly 31% year-to-date. The gains have come Continue reading Why AbbVie’s Global Alliance With Galapagos Is Good News for Investors
US-based clinical stage drug discovery and development firm Celtaxsys has completed Phase I clinical trial of its drug CTX-4430 to treat patients with cystic fibrosis (CF) lung disease.
Celtaxsys Aus, the company’s Australian subsidiary, has carried out the first of two clinical trials in Continue reading Celtaxsys completes Phase I trial of cystic fibrosis drug
Of the over 1,900 errors already reported in the gene responsible for cystic fibrosis (CF), it is unclear how many of them actually contribute to the inherited disease. Now a team of researchers reports significant headway in figuring out which mutations are benign and which are deleterious. Continue reading Scientists pinpoint 105 additional genetic errors that cause cystic fibrosis